Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins

Biomaterials

Volumn 32, Issue 1, 2011, Pages 162-169

  Imai, Sunao ^a   Nagano, Kazuya ^a   Yoshida, Yasunobu ^a   Okamura, Takayuki ^a   Yamashita, Takuya ^a,b   Abe, Yasuhiro ^a   Yoshikawa, Tomoaki ^a,b   Yoshioka, Yasuo ^a,b   Kamada, Haruhiko ^a,b   Mukai, Yohei ^a,b   Nakagawa, Shinsaku ^b   Tsutsumi, Yasuo ^a,b   Tsunoda, Shin ichi ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody; Cancer; Image analysis; Immunochemistry; Molecular biology; Protein

Indexed keywords

ANTIBODY LIBRARY; BREAST CANCER CELLS; BREAST TUMOR; CANCER; DISEASED TISSUES; DRUG DEVELOPMENT; EFFICIENT METHOD; EXPRESSION PROFILE; GEL ELECTROPHORESIS ANALYSIS; IMMUNOCHEMISTRY; IMMUNOSTAINING; MASS SPECTROMETRY ANALYSIS; NITROCELLULOSE MEMBRANES; PROTEOMICS;

BACTERIOPHAGES; BIOCHEMISTRY; ELECTROPHORESIS; GELS; HISTOLOGY; IMAGE ANALYSIS; MASS SPECTROMETRY; MOLECULAR BIOLOGY; MOLECULAR STRUCTURE; NITROCELLULOSE; TUMORS;

ANTIBODIES;

BIOLOGICAL MARKER; CROSS REACTING ANTIBODY; CYTOKERATIN 8; EPHRIN RECEPTOR; EPHRIN RECEPTOR A10; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRYPSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY LIBRARY; ARTICLE; BACTERIOPHAGE; BREAST CANCER; CANCER CELL; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TISSUE MICROARRAY; TWO DIMENSIONAL DIFFERENTIAL IN GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICROARRAY ANALYSIS; NEOPLASM PROTEINS; PEPTIDE LIBRARY; PROTEOME; PROTEOMICS; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 78349309759     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.030     Document Type: Article

References (36)

1. Hanash S. Disease proteomics. Nature 2003, 422(6928):226-232.
2. Kavallaris M., Marshall G.M. Proteomics and disease: opportunities and challenges. Med J Aust 2005, 182(11):575-579.
3. Oh-Ishi M., Maeda T. Disease proteomics of high-molecular-mass proteins by two-dimensional gel electrophoresis with agarose gels in the first dimension (Agarose 2-DE). J Chromatogr B Analyt Technol Biomed Life Sci 2007, 849(1-2):211-222.
4. Chaga G.S. Antibody arrays for determination of relative protein abundances. Methods Mol Biol 2008, 441:129-151.
5. Kaufmann H., Bailey J.E., Fussenegger M. Use of antibodies for detection of phosphorylated proteins separated by two-dimensional gel electrophoresis. Proteomics 2001, 1(2):194-199.
6. Xu Z.W., Zhang T., Song C.J., Li Q., Zhuang R., Yang K., et al. Application of sandwich ELISA for detecting tag fusion proteins in high throughput. Appl Microbiol Biotechnol 2008, 81(1):183-189.
7. Au N.H., Gown A.M., Cheang M., Huntsman D., Yorida E., Elliott W.M., et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004, 12(3):240-247.
8. de Jong D., Xie W., Rosenwald A., Chhanabhai M., Gaulard P., Klapper W., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009, 62(2):128-138.
9. Kozarova A., Petrinac S., Ali A., Hudson J.W. Array of informatics: applications in modern research. J Proteome Res 2006, 5(5):1051-1059.
10. Rimm D.L., Camp R.L., Charette L.A., Costa J., Olsen D.A., Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001, 7(1):24-31.
11. Tawfik El-Mansi M., Williams A.R. Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. Int J Gynecol Cancer 2006, 16(3):1225-1233.
12. Asadi A., Pourfathollah A.A., Mahdavi M., Eftekharian M.M., Moazzeni S.M. Preparation of antibody against horseradish peroxidase using hybridoma technology. Hum Antibodies 2008, 17(3-4):73-78.
13. Hadas E., Theilen G. Production of monoclonal antibodies. The effect of hybridoma concentration on the yield of antibody-producing clones. J Immunol Methods 1987, 96(1):3-6.
14. Makonkawkeyoon L., Pharephan S., Makonkawkeyoon S. Production of a mouse hybridoma secreting monoclonal antibody highly specific to hemoglobin Bart's (gamma4). Lab Hematol 2006, 12(4):193-200.
15. McKinney K.L., Dilwith R., Belfort G. Optimizing antibody production in batch hybridoma cell culture. J Biotechnol 1995, 40(1):31-48.
16. Barbas C.F., Kang A.S., Lerner R.A., Benkovic S.J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 1991, 88(18):7978-7982.
17. Coomber D.W. Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol 2002, 178:133-145.
18. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348(6301):552-554.
19. Okamoto T., Mukai Y., Yoshioka Y., Shibata H., Kawamura M., Yamamoto Y., et al. Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. Biochem Biophys Res Commun 2004, 323(2):583-591.
20. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228(4705):1315-1317.
21. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C., et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996, 14(3):309-314.
22. Imai S., Mukai Y., Nagano K., Shibata H., Sugita T., Abe Y., et al. Quality enhancement of the non-immune phage scFv library to isolate effective antibodies. Biol Pharm Bull 2006, 29(7):1325-1330.
23. Xu J.L., Davis M.M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 2000, 13(1):37-45.
24. Schier R., Marks J.D. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas 1996, 7(3):97-105.
25. Sheets M.D., Amersdorfer P., Finnern R., Sargent P., Lindquist E., Schier R., et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A 1998, 95(11):6157-6162.
26. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58(13):2825-2831.
27. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17(17):2235-2249.
28. Amar S., Moreno-Aspitia A., Perez E.A. Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2008, 109(1):1-7.
29. Nahta R., Esteva F.J. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 2004, 53(2):186-190.
30. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3(5):269-280.
31. Plummer R., Attard G., Pacey S., Li L., Razak A., Perrett R., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007, 13(20):6187-6194.
32. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007, 25(11):1390-1395.
33. Vannucchi S., Chiantore M.V., Fiorucci G., Percario Z.A., Leone S., Affabris E., et al. TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells. Oncogene 2005, 24(15):2536-2546.
34. Ditzel H.J., Strik M.C., Larsen M.K., Willis A.C., Waseem A., Kejling K., et al. Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. J Biol Chem 2002, 277(24):21712-21722.
35. Fukunaga Y., Bandoh S., Fujita J., Yang Y., Ueda Y., Hojo S., et al. Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients. Lung Cancer 2002, 38(1):31-38.
36. Wolff J.M., Borchers H., Brehmer B., Brauers A., Jakse G. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia. Urol Int 1998, 60(3):152-155.